EMERGING THERAPY FOR DENGUE
Debasmita Mukherjee*, Dr. Falguni Patra and Dr. Beduin Mahanti
ABSTRACT
Dengue fever, commonly known as break bone fever is a flu-like illness caused by the Dengue virus. Dengue, a vector born viral fever caused by the various stain of flavivirus and transmitted by female Aedes mosquitoes , remain a therapeutically challenging disease despite various antiviral drug (ribivirin, glycyrrhizin, and 6-aziridine)are under evaluation , its severity is more pronounced in immune -compromised patients , also presents with Dengue fever sequel as dengue hemorrhagic fever and Dengue hemorrhagic shock. Each serotype is sufficiently different that there is no cross- protection and epidemics caused by multiple serotypes can occur. However, several classes of agents are in under investigation as potential anti- dengue drugs, including direct host modulators, antiviral, and RNAi therapeutics. Dengue is caused by the Dengue virus (DENV). DENV is a single-stranded RNA positive -strand virus. The serotype is sufficiently different thet there is no cross-protection and epidemics caused by multiple serotypes can occur. The incidence of dengue has grown around the world in recent a period of ten years. Treatments, causes, anti dengue drugs in development will be reviewed here.
Keywords: Aedes Mosquito, Dengue Virus, Febrole, Epidemic, Serotype, Treatment, Homorrhagic, Vector, Flu.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
